Ectopic lymphoid neogenesis in rheumatic autoimmune diseases

Nature Reviews Rheumatology

Volumn 13, Issue 3, 2017, Pages 141-154

  Bombardieri, Michele ^a   Lewis, Myles ^a   Pitzalis, Costantino ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AUTOANTIBODY; CHEMOKINE RECEPTOR CCR7; CXCL13 CHEMOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 7; LYMPHOTOXIN BETA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; OSTEOCLAST DIFFERENTIATION FACTOR; RITUXIMAB; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANTIBODY PRODUCTION; AUTOIMMUNITY; CELL MATURATION; CELL MIGRATION; CELL SURVIVAL; CLINICAL OUTCOME; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ECTOPIC LYMPHOID NEOGENESIS; GENERAL ASPECTS OF DISEASE; HELPER CELL; HUMAN; IMMUNE RESPONSE; MYOSITIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLASMA CELL; PREVALENCE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TERTIARY LYMPHOID STRUCTURE; TISSUE DISTRIBUTION; TREATMENT RESPONSE; AUTOIMMUNE DISEASE; EPIDEMIOLOGY; PATHOLOGY; RHEUMATIC DISEASE;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREVALENCE; RHEUMATIC DISEASES; SJOGREN'S SYNDROME; TERTIARY LYMPHOID STRUCTURES;

EID: 85012920165     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2016.217     Document Type: Review

References (119)

1. Pitzalis, C., Jones, G. W., Bombardieri, M. &Jones, S. A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447-462 (2014).
2. McInnes, I. B. &Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205-2219 (2011).
3. Dennis, G. Jr et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res. Ther. 16, R90 (2014).
4. Humby, F. et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 6, e1 (2009).
5. Klimiuk, P. A., Goronzy, J. J., Bjor nsson, J., Beckenbaugh, R. D. &Weyand, C. M. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am. J. Pathol. 151, 1311-1319 (1997).
6. Manzo, A. et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur. J. Immunol. 35, 1347-1359 (2005).
7. Pitzalis, C., Kelly, S. &Humby, F. New learnings on the pathophysiology of RA from synovial biopsies. Curr. Opin. Rheumatol. 25, 334-344 (2013).
8. Takemura, S. et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 167, 1072-1080 (2001).
9. Bugatti, S. et al. Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. Arthritis Rheum. 52, 3448-3459 (2005).
10. Rangel-Moreno, J. et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J. Clin. Invest. 116, 3183-3194 (2006).
11. Thurlings, R. M. et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann. Rheum. Dis. 67, 917-925 (2008).
12. Thurlings, R. M. et al. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum. 58, 1582-1589 (2008).
13. Vos, K. et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 56, 772-778 (2007).
14. Yanni, G., Whelan, A., Feighery, C. &Bresnihan, B. Analysis of cell populations in rheumatoid arthritis synovial tissues. Semin. Arthritis Rheum. 21, 393-399 (1992).
15. Manzo, A., Bombardieri, M., Humby, F. &Pitzalis, C. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol. Rev. 233, 267-285 (2010).
16. Aziz, K. E., McCluskey, P. J. &Wakefield, D. Characterisation of follicular dendritic cells in labial salivary glands of patients with primary Sjogren syndrome: comparison with tonsillar lymphoid follicles. Ann. Rheum. Dis. 56, 140-143 (1997).
17. Barone, F. et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. Arthritis Rheum. 52, 1773-1784 (2005).
18. Croia, C. et al. Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjogren's syndrome. Arthritis Rheumatol. 66, 2545-2557 (2014).
19. Jonsson, M. V., Skarstein, K., Jonsson, R. &Brun, J. G. Serological implications of germinal center-like structures in primary Sjögren's syndrome. J. Rheumatol. 34, 2044-2049 (2007).
20. Stott, D. I., Hiepe, F., Hummel, M., Steinhauser, G. &Berek, C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J. Clin. Invest. 102, 938-946 (1998).
21. Theander, E. et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann. Rheum. Dis. 70, 1363-1368 (2011).
22. Pijpe, J. et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 46, 335-341 (2007).
23. Bombardieri, M. et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjögren's syndrome. J. Immunol. 179, 4929-4938 (2007).
24. Chang, A. et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 186, 1849-1860 (2011).
25. Shen, Y. et al. Association of intrarenal B-cell infiltrates with clinical outcome in lupus nephritis: a study of 192 cases. Clin. Dev. Immunol. 2012, 967584 (2012).
26. Neusser, M. A. et al. Intrarenal production of B-cell survival factors in human lupus nephritis. Mod. Pathol. 24, 98-107 (2011).
27. Liu, Z. et al. Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum. 63, 219-229 (2011).
28. Mathian, A., Gallegos, M., Pascual, V., Banchereau, J. &Koutouzov, S. Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZBxNZW)F1 mice but not in BALB/c mice. Eur. J. Immunol. 41, 863-872 (2011).
29. Mahevas, M. et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J. Clin. Invest. 123, 432-442 (2013).
30. Domeier, P. P. et al. IFN-γ receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. J. Exp. Med. 213, 715-732 (2016).
31. Jackson, S. W. et al. B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J. Exp. Med. 213, 733-750 (2016).
32. Arahata, K. &Engel, A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 16, 193-208 (1984).
33. De Bleecker, J. L., Engel, A. G. &Butcher, E. C. Peripheral lymphoid tissue-like adhesion molecule expression in nodular infiltrates in inflammatory myopathies. Neuromuscul. Disord. 6, 255-260 (1996).
34. Lopez De Padilla, C. M., Vallejo, A. N., Lacomis, D., McNallan, K. &Reed, A. M. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum. 60, 1160-1172 (2009).
35. Salajegheh, M. et al. Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 42, 576-583 (2010).
36. Bradshaw, E. M. et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J. Immunol. 178, 547-556 (2007).
37. Drayton, D. L., Liao, S., Mounzer, R. H. &Ruddle, N. H. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7, 344-353 (2006).
38. Jones, G. W. et al. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. J. Exp. Med. 212, 1793-1802 (2015).
39. Mebius, R. E. Organogenesis of lymphoid tissues. Nat. Rev. Immunol. 3, 292-303 (2003).
40. van de Pavert, S. A. &Mebius, R. E. New insights into the development of lymphoid tissues. Nat. Rev. Immunol. 10, 664-674 (2010).
41. Randall, T. D. &Mebius, R. E. The development and function of mucosal lymphoid tissues: a balancing act with micro-organisms. Mucosal Immunol. 7, 455-466 (2014).
42. Browning, J. L. et al. Lymphotoxin-β receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity 23, 539-550 (2005).
43. Bugatti, S. et al. High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology (Oxford) 53, 1886-1895 (2014).
44. Salomonsson, S. et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjφgren's syndrome. Arthritis Rheum. 48, 3187-3201 (2003).
45. Weyand, C. M. &Goronzy, J. J. Ectopic germinal center formation in rheumatoid synovitis. Ann. NY Acad. Sci. 987, 140-149 (2003).
46. Link, A. et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat. Immunol. 8, 1255-1265 (2007).
47. Manzo, A. et al. CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. Am. J. Pathol. 171, 1549-1562 (2007).
48. Barone, F. et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjφgren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J. Immunol. 180, 5130-5140 (2008).
49. Carlsen, H. S., Baekkevold, E. S., Morton, H. C., Haraldsen, G. &Brandtzaeg, P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood 104, 3021-3027 (2004).
50. Kobayashi, S. et al. A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium. Arthritis Rheum. 65, 3063-3072 (2013).
51. Manzo, A. et al. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum. 58, 3377-3387 (2008).
52. GeurtsvanKessel, C. H. et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J. Exp. Med. 206, 2339-2349 (2009).
53. Amft, N. et al. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome. Arthritis Rheum. 44, 2633-2641 (2001).
54. Xanthou, G. et al. "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum. 44, 408-418 (2001).
55. Peters, A. et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35, 986-996 (2011).
56. Rangel-Moreno, J. et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12, 639-646 (2011).
57. Sawa, S. et al. Lineage relationship analysis of RORγt+ innate lymphoid cells. Science 330, 665-669 (2010).
58. Chabaud, M. et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42, 963-970 (1999).
59. Canete, J. D. et al. Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. Arthritis Res. Ther. 17, 173 (2015).
60. Dudakov, J. A., Hanash, A. M. &van den Brink, M. R. Interleukin-22: immunobiology and pathology. Annu. Rev. Immunol. 33, 747-785 (2015).
61. Barone, F. et al. IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc. Natl Acad. Sci. USA 112, 11024-11029 (2015).
62. Bombardieri, M. et al. Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice. J. Immunol. 189, 3767-3776 (2012).
63. Ciccia, F. et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann. Rheum. Dis. 71, 295-301 (2012).
64. Slight, S. R. et al. CXCR5+ T helper cells mediate protective immunity against tuberculosis. J. Clin. Invest. 123, 712-726 (2013).
65. Shulman, Z. et al. Dynamic signaling by T follicular helper cells during germinal center B cell selection. Science 345, 1058-1062 (2014).
66. Breitfeld, D. et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192, 1545-1552 (2000).
67. Karnell, J. L. &Ettinger, R. The interplay of IL-21 and BAFF in the formation and maintenance of human B cell memory. Front. Immunol. 3, 2 (2012).
68. Liu, D. et al. T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction. Nature 517, 214-218 (2015).
69. Jungel, A. et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum. 50, 1468-1476 (2004).
70. Kwok, S. K. et al. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum. 64, 740-751 (2012).
71. Young, D. A. et al. Blockade of the interleukin-21/ interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56, 1152-1163 (2007).
72. Liu, H., Liu, G., Gong, L., Zhang, Y. &Jiang, G. Local suppression of IL-21 in submandibular glands retards the development of Sjogren's syndrome in non-obese diabetic mice. J. Oral Pathol. Med. 41, 728-735 (2012).
73. Gong, Y. Z. et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjφgren's syndrome. J. Autoimmun. 51, 57-66 (2014).
74. Stumhofer, J. S. et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7, 937-945 (2006).
75. Lee, B. H., Carcamo, W. C., Chiorini, J. A., Peck, A. B. &Nguyen, C. Q. Gene therapy using IL-27 ameliorates Sjφgren's syndrome-like autoimmune exocrinopathy. Arthritis Res. Ther. 14, R172 (2012).
76. Batten, M. et al. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J. Exp. Med. 207, 2895-2906 (2010).
77. Sage, P. T. &Sharpe, A. H. T follicular regulatory cells in the regulation of B cell responses. Trends Immunol. 36, 410-418 (2015).
78. Corsiero, E. et al. Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs. Ann. Rheum. Dis. 75, 1866-1875 (2015).
79. Scheel, T., Gursche, A., Zacher, J., Haupl, T. &Berek, C. V-Region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis. Arthritis Rheum. 63, 63-72 (2011).
80. Bombardieri, M. et al. A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Ann. Rheum. Dis. 70, 1857-1865 (2011).
81. Le Pottier, L. et al. Ectopic germinal centers are rare in Sjφgren's syndrome salivary glands and do not exclude autoreactive B cells. J. Immunol. 182, 3540-3547 (2009).
82. Canete, J. D. et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann. Rheum. Dis. 66, 720-726 (2007).
83. Cantaert, T. et al. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J. Immunol. 181, 785-794 (2008).
84. Canete, J. D. et al. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor α therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68, 751-756 (2009).
85. Rosengren, S. et al. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res. Ther. 10, R105 (2008).
86. Amara, K. et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J. Exp. Med. 210, 445-455 (2013).
87. Risselada, A. P., Looije, M. F., Kruize, A. A., Bijlsma, J. W. &van Roon, J. A. The role of ectopic germinal centers in the immunopathology of primary Sjφgren's syndrome: a systematic review. Semin. Arthritis Rheum. 42, 368-376 (2013).
88. Croia, C. et al. Epstein-Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis. Ann. Rheum. Dis. 72, 1559-1568 (2013).
89. Doorenspleet, M. E. et al. Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity. Ann. Rheum. Dis. 73, 756-762 (2014).
90. Klarenbeek, P. L. et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann. Rheum. Dis. 71, 1088-1093 (2012).
91. Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. &Corcoran, L. M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160-171 (2015).
92. Szyszko, E. A. et al. Salivary glands of primary Sjφgren's syndrome patients express factors vital for plasma cell survival. Arthritis Res. Ther. 13, R2 (2011).
93. Kim, K. W. et al. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum. 56, 1076-1086 (2007).
94. Noss, E. H., Nguyen, H. N., Chang, S. K., Watts, G. F. &Brenner, M. B. Genetic polymorphism directs IL-6 expression in fibroblasts but not selected other cell types. Proc. Natl Acad. Sci. USA 112, 14948-14953 (2015).
95. Xu, X. et al. Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritis. Scand. J. Immunol. 70, 309-316 (2009).
96. Lanfant-Weybel, K. et al. Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy-A pilot study from the VErA cohort. Joint Bone Spine 79, 574-580 (2012).
97. van de Sande, M. G. et al. Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time? Ann. Rheum. Dis. 70, 700-703 (2011).
98. Royer, B. et al. Lymphomas in patients with Sjögren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 90, 766-775 (1997).
99. Bende, R. J. et al. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J. Exp. Med. 201, 1229-1241 (2005).
100. Martin, T. et al. Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum. 43, 908-916 (2000).
101. Gasparotto, D. et al. Extrasalivary lymphoma development in Sjögren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum. 48, 3181-3186 (2003).
102. Espeli, M. et al. Local renal autoantibody production in lupus nephritis. J. Am. Soc. Nephrol. 22, 296-305 (2011).
103. Klaasen, R. et al. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum. 60, 3217-3224 (2009).
104. Kavanaugh, A. et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann. Rheum. Dis. 67, 402-408 (2008).
105. Delli, K. et al. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann. Rheum. Dis. 75, 1933-1938 (2016).
106. Hamza, N. et al. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy. Ann. Rheum. Dis. 71, 1881-1887 (2012).
107. Pijpe, J. et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum. 60, 3251-3256 (2009).
108. Quartuccio, L. et al. Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol. J. 2, 38-43 (2008).
109. Teng, Y. K., Levarht, E. W., Toes, R. E., Huizinga, T. W. &van Laar, J. M. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann. Rheum. Dis. 68, 1011-1016 (2009).
110. Rosengren, S., Wei, N., Kalunian, K. C., Kavanaugh, A. &Boyle, D. L. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 50, 603-610 (2011).
111. Buch, M. H. et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology (Oxford) 47, 1469-1475 (2008).
112. Das, S. et al. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann. Rheum. Dis. 73, 909-912 (2014).
113. Adler, S. et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: a pilot study. Arthritis Care Res. (Hoboken) 65, 1862-1868 (2013).
114. Fava, R. A. et al. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J. Immunol. 171, 115-126 (2003).
115. Gatumu, M. K. et al. Blockade of lymphotoxin-β receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res. Ther. 11, R24 (2009).
116. St.Clair, E. W. et al. The clinical efficacy and safety of baminercept, a lymphotoxin-β receptor fusion protein, in primary Sjφgren's syndrome: results from a randomized, double-blind, placebo-controlled phase II trial [abstract]. Arthritis Rheumatol. 67 (Suppl. 10), 3203 (2015).
117. Hu, Y. L., Metz, D. P., Chung, J., Siu, G. &Zhang, M. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J. Immunol. 182, 1421-1428 (2009).
118. Alzabin, S. et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann. Rheum. Dis. 71, 1741-1748 (2012).
119. Ferrari, M., Onuoha, S. C. &Pitzalis, C. Trojan horses and guided missiles: targeted therapies in the war on arthritis. Nat. Rev. Rheumatol. 11, 328-337 (2015).